Novo Nordisk: Why The Market Sell-Off On CagriSema Data May Be Justified
Novo Nordisk's CagriSema Phase 3 data showed 22.7% weight loss, missing the company's own 25% target, causing a 20% drop in ...
Zepbound helps shed more weight than Wegovy, Eli Lilly study says
A new study put Eli Lilly's Zepbound and Novo Nordisk's Wegovy to the test. Here's which one will help you lose more weight.
Novo’s New Deal May End Wegovy Shortages. It Could Reshape the Pharma Industry Along the Way.
The end of Novo Nordisk’s supply problems could bring new headaches for the rest of the pharmaceutical industry, which now ...
Novo Nordisk Stock: A Rare Buying Opportunity
Financial writer sees Novo Nordisk's stock drop as a buying opportunity after disappointing trial results, citing strong ...
Focus: In weight loss battle, Novo and Lilly face growing offensive from licenced copies
As Novo Nordisk and Eli Lilly expand sales of their popular diabetes and weight-loss drugs, cheaper copies of their patented ...
24/7 Wall St2d
Novo Nordisk A/S (NVO) Price Prediction and Forecast 2025-2030
When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...
FierceBiotech3d
Novo Nordisk taps Photys for $186M cardiometabolic collab
With Novo Nordisk’s name already synonymous with treatments for diabetes and obesity, the Danish drugmaker has been making a ...
FiercePharma3d
After studies flag possible link between Novo's Ozempic and rare eye disorder, Danish agency calls for probe
It’s not a new question, but it is one that is gaining increased traction: Is there a link between Novo Nordisk’s diabetes ...